600% Kurspotential YM Biosciences 911799

das war wichtig. gutes zeichen

schade erstmal

Rauf runter rauf runter...

Ich will endlich mal die 1,50 € sehen kommen ;-)  

3 kandidaten warten auf die zulassung

Irgend wann muss es ja mal los gehen!  

aber ich hab ein ganz gutes gefühl bei der sache
immerhin was :-)

Wer kann nur seine shares so heraus schmeissen?

Glückwünsch an den Käufer!  

kann nicht mehr lange gehen! der ausgangslage ist perfekt um nach oben endlich auszubrechen

sorry

mal sehen wie der markt reagiert

entscheidend ändern wird es sich erst, wenn eine Phase 3 endlich positiv abschliesst und die Genehmigung für das Produkt erteilt wird.

 

schönen Vatertag

 

so jetzt kann Kutzke den Kurs hochpeitschen  

aber achte sind drin in Sack und Tüten
holla
Kutzke ist doof hat aber die Pimpe und sitzt am richtigen hebel
Kutzke Deine Frau ist nicht schön hat aber den richtigen Mann geheiratet!
Daaaaaaaaaaanke!  

 

so gehts erstmal seitwärts

...es geht anscheinend langsam los :)  

he Best Investing Ideas in Health Care
By Motley Fool Staff
July 12, 2010 | Comments (0)

Recs
3

Email
 Share
Print
TRUE
Centrue Financia
Rate TRUE
CAPS Rating 0/5 Stars
$2.05 $0.00 (0.00%)

Netflix Hits $100!
David Gardner called Netflix in 2004 at $15.42. He’s up 546% as of April 23rd. See what David’s recommending that you buy NEXT.
Click Here Now
Chasing highfliers is a sucker's game. But tracking monthly trends across the market can lead to great investment ideas, while shedding new light on stocks you already have in your portfolio.

Let's take a look at the biggest movers in health care. These stocks -- which include companies from the pharmaceutical and biotechnology sectors -- have clocked some of the biggest gains during the last month.

Health-care market movers

Company
Industry
CAPS Rating
30-Day Return
Market Cap
Price / Earnings
Biovail (NYSE: BVF)
Pharmaceuticals
***
31.78%
3.04B
29.16
Arena Pharmaceuticals (Nasdaq: ARNA)
Biotechnology
***
29.83%
381.73M
N/A
AVANIR Pharmaceuticals (Nasdaq: AVNR)
Pharmaceuticals
****
22.51%
309.17M
13
Neurocrine Biosciences (Nasdaq: NBIX)
Biotechnology
**
22.41%
305.96M
91.67
Those returns are certainly eye-catching. But do these highfliers have staying power?

Let's see what The Motley Fool CAPS community (more than 165,000 investors strong) has to say about the best plays in the health-care market.

And the next big winners are ...
The following health-care stocks are of similar size, and in comparable industries, to the ones in the previous chart. However, CAPS members think these companies have more promising future returns than those already making waves.

CAPS community health-care favorites

Company
Industry
CAPS Rating
Market Cap
Price / Earnings
Fools Saying Outperform
Dr. Reddy's Laboratories (NYSE: RDY)
(Alternative to BVF)
Pharmaceuticals
****
5.26B
29.16
495 of 522
YM BioSciences (AMEX: YMI)
(Alternative to ARNA and NBIX)
Pharmaceuticals and biotechnology
****
95.76M
33.35
84 of 85
Obagi Medical Products (Nasdaq: OMPI)
(Alternative to AVNR)
Pharmaceuticals
*****
250.25M
35
276 of 301
Of course, some of today's winners might continue to rack up outsize returns. But isn't it better to snag tomorrow's winners before they start running up?

...dann können 3 Euro und mehr drin sein  

welche Zulassung?
Wir warten auf P2 bzw.P3 Daten von Nimo.
Ein Zulassungsantrag wurde meines Wissens nicht gestellt.
Macht ja auch keinen Sinn vor guten P3 Daten.
Falls ich falsch liege,bitte ich um Korrektur.
Gruß Wilbär.

 

sehr gut das wir in den nächsten monaten einen sprung von 25% plus machen.  

bitte präzisiere Deine Aussage,am besten mit Fakten.
Reine Provokation bringt doch nichts.Gruß Wilbär.

YM BioSciences granted Orphan Drug Designation for CYT387

-JAK1/2 inhibitor currently in Phase II clinical study in myelofibrosis-
MISSISSAUGA, ON, Aug. 10 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX:YM), announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the Company's highly-selective JAK1/2 inhibitor, CYT387, for the treatment of myelofibrosis, a chronic debilitating unmet medical need, in which a patient's bone marrow is replaced by scar tissue, and for which treatment options are limited or unsatisfactory.
Orphan Drug Designation is granted to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the U.S. The designation provides the drug developer with a seven-year period of U.S. marketing exclusivity upon marketing approval for the designated indication, as well as with tax credits for clinical research costs, the ability to apply for annual grant funding, clinical research trial design assistance and the waiver of Prescription Drug User Fee Act (PDUFA) filing fees.
"CYT387 is a potent, oral JAK1/2 inhibitor that has been demonstrating very favorable biological activity data in our ongoing Phase I/II trial in myelofibrosis and the granting of Orphan Drug Designation is a key regulatory milestone for our CYT387 clinical development program," said Dr. Nick Glover, COO of YM BioSciences. "This event provides us with further support for our expanding commitment to this promising drug as we continue to broaden our investment in our CYT387 development program while concentrating on advancing the molecule towards an NDA-enabling study in myelofibrosis."
The compound is currently being investigated in an oral Phase I/II clinical study in myelofibrosis patients at Mayo Clinic, Rochester, New York with Dr. Ayalew Tefferi, Professor, Hematology as Study Chair. The company intends to expand the present program up to 120 patients at a maximum of six centers in the U.S., Canada and Australia, subject to regulatory approval.
The Company recently provided an update on the progress of the clinical study, including the finalization of dose-escalation, identification of reversible dose-limiting toxicities and commencement of dosing in the Phase II dose-confirmation portion of the study. Promising evidence of biological activity, including significant spleen size reduction, improvement in constitutional symptoms and favorable hematological changes, was also reported. Detailed safety and activity data for CYT387 are planned to be presented at the American Society of Hematology (ASH) meeting in Orlando, Florida in December this year.
About CYT387
CYT387 is an inhibitor of the kinase enzymes JAK1 and JAK2, which have been implicated in a family of hematological conditions known as myeloproliferative neoplasms, including myelofibrosis, but as well in numerous disorders including indications in hematology, oncology and inflammatory diseases.
   -   Potent, oral JAK1/2 inhibitor
   -   Excellent selectivity against a panel of over 150 structurally
       diverse protein kinases
   -   Favorable preclinical safety profile
   -   Direct preclinical comparison with other JAK2 inhibitors indicates
       that very few of the other compounds in development match the potency
       and selectivity of CYT387.

nicht schlecht,verkürzt eine ev.Zulassung von CYT387 gewaltig.
Jetzt noch pos.P2/3 Daten von Nimo,sollten ja bald kommen,dann gibts einen ordentlichen Schub gen Norden.
Gruß Wilbär.

Wichtig wäre, über 1,60 in USA zu schliessen.

Also Toronto nachmachen, dort sind wir schon bei 1.61 Can. Dollar!!!